Hong Kong SAR
-
A senior debt capital markets banker at HSBC in Hong Kong is moving to Barclays, GlobalCapital Asia has learnt. -
Hong Kong property developer Sino Group has converted a HK$1bn ($129m) loan sealed last year into a sustainability-linked deal, in line with its goals of embracing ESG across its operations.
-
Medlive Technology and Brii Biosciences are tapping investors for a combined HK$6.7bn ($863m).
-
Bank of Communications Hong Kong has sold its first Basel-III compliant tier two bond. The deal was four times subscribed at its peak.
-
Hong Kong jewellery company Chow Tai Fook has received strong support for its latest loan, allowing it to almost double the deal size.
-
Kindstar Globalgene Technology and Dexin Services Group both rolled out their Hong Kong IPOs on Tuesday.
-
Chinese biotechnology company Keymed Biosciences has hit the market with an up to HK$3.1bn ($400.1m) IPO.
-
SCE Intelligent Commercial Management has raised HK$1.85bn ($238.3m) after pricing its IPO at the bottom of the guidance range.
-
Xpeng has kicked off its Hong Kong secondary listing, the first from a Chinese electric vehicle maker.
-
Chaoju Eye Care Holdings is gauging investor appetite for a HK$1.81bn ($233m) listing on the Hong Kong Stock Exchange, becoming the latest healthcare related company to seek an IPO.
-
I have used Covid-19 as an excuse to avoid some unwanted social occasions over the last year or so, but a friend of mind has taken his Covid isolation to a new level.
-
Biopharmaceutical company HutchMed (China) pocketed HK$4.17bn ($537.1m) this week from its Hong Kong IPO.
